Immix Biopharma (NASDAQ:IMMX) Shares Climb 5.8% - Here's What Happened

Immix Biopharma logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Immix Biopharma shares rose 5.8% to about $7.45 on Friday, while trading volume was 84% below its average; the article did not identify a specific catalyst for the gain.
  • Analyst sentiment is broadly positive: eight analysts rate IMMX a Buy and one a Sell, with a “Moderate Buy” consensus and an average price target of $24.14.
  • The company reported quarterly EPS of -$0.19, matching consensus estimates. Several institutions disclosed new positions or increased holdings, and institutional investors own 11.26% of the shares.
  • MarketBeat previews top five stocks to own in December.

Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) shares traded up 5.8% during trading on Friday. The stock traded as high as $7.46 and last traded at $7.4490. 204,967 shares changed hands during trading, a decline of 84% from the average session volume of 1,305,224 shares. The stock had previously closed at $7.04.

Wall Street Analyst Weigh In

Several research analysts have commented on IMMX shares. Mizuho dropped their price target on Immix Biopharma from $23.00 to $22.00 and set an "outperform" rating on the stock in a research report on Wednesday. Morgan Stanley upped their target price on shares of Immix Biopharma from $20.00 to $21.00 and gave the stock an "overweight" rating in a research report on Wednesday. Citigroup restated a "market outperform" rating on shares of Immix Biopharma in a research report on Wednesday, September 30th. HC Wainwright lifted their price target on shares of Immix Biopharma from $25.00 to $27.00 and gave the company a "buy" rating in a research note on Monday. Finally, Needham & Company LLC increased their price objective on Immix Biopharma from $21.00 to $30.00 and gave the stock a "buy" rating in a research report on Tuesday, September 29th. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $24.14.

Read Our Latest Analysis on IMMX

Immix Biopharma Stock Performance

The stock has a market cap of $595.55 million, a P/E ratio of -8.55 and a beta of 0.29. The stock has a 50-day moving average price of $9.35 and a 200-day moving average price of $9.61.

Immix Biopharma (NASDAQ:IMMX - Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($0.19) EPS for the quarter, hitting the consensus estimate of ($0.19). Sell-side analysts forecast that Immix Biopharma, Inc. will post -0.75 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Immix Biopharma

Several hedge funds and other institutional investors have recently made changes to their positions in IMMX. Blue Owl Capital Holdings LP purchased a new stake in shares of Immix Biopharma during the second quarter valued at about $4,511,000. Bank of America Corp DE acquired a new position in shares of Immix Biopharma in the second quarter valued at about $4,260,000. Wellington Management Group LLP acquired a new position in Immix Biopharma in the 2nd quarter worth approximately $15,191,000. Tocqueville Asset Management L.P. acquired a new position in Immix Biopharma during the second quarter valued at $913,000. Finally, Velan Capital Investment Management LP grew its holdings in Immix Biopharma by 46.6% during the second quarter. Velan Capital Investment Management LP now owns 1,085,000 shares of the company's stock worth $11,186,000 after acquiring an additional 345,000 shares during the period. Hedge funds and other institutional investors own 11.26% of the company's stock.

Immix Biopharma Company Profile

(Get Free Report)

Immix Biopharma is a clinical-stage biopharmaceutical company developing cell therapies for serious diseases, with a focus on relapsed or refractory AL amyloidosis, a rare condition in which abnormal proteins build up in organs and tissues. The company's lead candidate, NXC-201, is an investigational CAR T-cell therapy designed to target BCMA, a protein found on certain plasma cells. It is being studied in clinical trials and has not been approved for commercial use. Immix Biopharma is based in the United States and is led by Chief Executive Officer Ilya Rachman.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Immix Biopharma Right Now?

Before you consider Immix Biopharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immix Biopharma wasn't on the list.

While Immix Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines